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Influence of tumour stage at breast cancer detection on survival 
in modern times: population based study in 173 797 patients
Sepideh Saadatmand,1 Reini Bretveld,2 Sabine Siesling,2,3 Madeleine M A Tilanus-Linthorst1 
ABSTRACT
ObjeCtives
To assess the influence of stage at breast cancer 
diagnosis, tumour biology, and treatment on survival 
in contemporary times of better (neo-)adjuvant 
systemic therapy.
Design
Prospective nationwide population based study.
setting
Nationwide Netherlands Cancer Registry.
PartiCiPants
Female patients with primary breast cancer diagnosed 
between 1999 and 2012 (n=173 797), subdivided into 
two time cohorts on the basis of breast cancer 
diagnosis: 1999-2005 (n=80 228) and 2006-12 
(n=93 569).
Main OutCOMe Measures
Relative survival was compared between the two 
cohorts. Influence of traditional prognostic factors on 
overall mortality was analysed with Cox regression for 
each cohort separately.
results
Compared with 1999-2005, patients from 2006-12 had 
smaller (≤T1 65% (n=60 570) v 60% (n=48 031); 
P<0.001), more often lymph node negative (N0 68% 
(n=63 544) v 65% (n=52 238); P<0.001) tumours, but 
they received more chemotherapy, hormonal therapy, 
and targeted therapy (neo-adjuvant/adjuvant systemic 
therapy 60% (n=56 402) v 53% (n=42 185); P<0.001). 
Median follow-up was 9.8 years for 1999-2005 and 3.9 
years for 2006-12. The relative five year survival rate in 
2006-12 was 96%, improved in all tumour and nodal 
stages compared with 1999-2005, and 100% in 
tumours ≤1 cm. In multivariable analyses adjusted for 
age and tumour type, overall mortality was decreased 
by surgery (especially breast conserving), 
radiotherapy, and systemic therapies. Mortality 
increased with progressing tumour size in both cohorts 
(2006-12 T1c v T1a: hazard ratio 1.54, 95% confidence 
interval 1.33 to 1.78), but without a significant 
difference in invasive breast cancers until 1 cm 
(2006-12 T1b v T1a: hazard ratio 1.04, 0.88 to 1.22), and 
independently with progressing number of positive 
lymph nodes (2006-12 N1 v N0: 1.25, 1.17 to 1.32).
COnClusiOns
Tumour stage at diagnosis of breast cancer still 
influences overall survival significantly in the current 
era of effective systemic therapy. Diagnosis of breast 
cancer at an early tumour stage remains vital.
Introduction
Rates of survival with breast cancer have increased sig-
nificantly all over the world in the past decades.1-3  In 
the United States, the five year relative survival rates for 
women with breast cancer have improved from approx-
imately 75% in 1975-77 to 90% in 2003-09.4  This 
improvement in survival can mainly be explained by an 
effect both of earlier diagnosis as a result of breast can-
cer screening and awareness and of better treatment 
options.5 6
The risk of metastases and death increases with both 
breast cancer size at detection and number of axillary 
lymph nodes involved.7-10  Screening aims to improve 
survival by decreasing the risk of metastases through 
early detection of breast cancer. In the Netherlands, the 
national breast screening programme with biennial 
mammography was implemented for all women aged 
50-69 years in 1989, and in 1998 the programme was 
extended to age 71-75 years.11
Next to tumour size and lymph node involvement, 
cancer related factors that influence survival are 
tumour grade, hormone receptor status, and human 
epidermal growth factor receptor 2 (HER2).8-12  Surgery, 
the cornerstone of breast cancer treatment, changed in 
the study period: to assess lymph node positivity, senti-
nel lymph node biopsy was first described in Dutch 
guidelines in 1999,13  although regional implementation 
had already started. The proportion of patients with 
early stage breast cancer who had sentinel lymph node 
biopsy increased from approximately 9% in 1998 to 
more than 70% in 2003.14  Recently, Mittendorf et  al 
published data indicating that in patients with small 
breast cancers lymph node micro-metastases are not of 
any prognostic value.12 An explanation might be the 
increasing effectiveness of systemic  therapy.
WhAT IS AlReAdy knoWn on ThIS TopIC
Survival decreases with increasing tumour size and number of positive lymph 
nodes at detection of breast cancer, but data on these prognostic factors in patient 
cohorts after 2004 are scarce
(Neo-)adjuvant systemic therapies have improved significantly since 2004, and 
breast cancer survival rates have increased
To what extent stage at breast cancer detection, in terms of tumour size and number 
of positive lymph nodes, still determines survival in contemporary times is 
unknown
WhAT ThIS STudy AddS
Relative survival of female breast cancer patients in a Dutch nationwide population 
based study of two time cohorts (1999-2005 and 2006-12) improved from 91% to 
96% at five years’ follow up
Tumour size and nodal status still have a significant and major influence on overall 
mortality independent of age and tumour biology in the current era of more 
conservative surgery and newer systemic (neo-)adjuvant therapies
Early stage at detection is vital; surgery is crucial, and more conservative surgery is 
more favourable
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In more recent years, (neo-)adjuvant systemic treat-
ment for breast cancer has improved considerably and 
is applied more often. Improvements include the use of 
trastuzumab, which significantly increases both short 
term and long term prognosis in HER2 positive breast 
cancer patients.15 16  Trastuzumab treatment was imple-
mented in the Netherlands between 2005 and 2006.17 18 
Moreover, a switch to more effective chemotherapy reg-
imens has occurred. CMF (cyclophosphamide, metho-
trexate, 5-fluorouracil) was prescribed to 90% of breast 
cancer patients receiving chemotherapy in 2000 and to 
almost none in 2005.19  It was gradually replaced by the 
more effective anthracyclines (4% use in 2000 to 96% in 
2005), which in turn were partly replaced by regimens 
containing taxane.19
Data published on the effect of screening and better 
treatment options on survival were based on cohorts of 
patients with breast cancer diagnosed in 2004 at the 
latest, and changes to more recent systemic therapy 
had not yet occurred. Traditional prognostic factors, 
such as tumour size and number of positive lymph 
nodes, may no longer predict survival in the current era 
of new systemic therapy; and if these factors do affect 
survival, the size of this effect is unknown. To quantify 
the effect of traditional prognostic factors, both long 
term and in the current era, we describe overall survival 
of female patients with breast cancer from two time 
cohorts (1999-2005 and 2006-12) in a nationwide popu-
lation based study using data from the Netherlands 
Cancer Registry.
Methods
Patient population
We selected women diagnosed as having primary breast 
cancer between 1 January 1999 and 31 December 2012 
from the Netherlands Cancer Registry. We excluded 
patients with a previous history of invasive cancer or 
lack of information on both clinical and pathological 
tumour size.
The Netherlands Cancer Registry is a nationwide pro-
spective population based cancer registry in which all 
newly pathologically confirmed malignancies in the 
Netherlands are recorded. New malignancies are 
detected through the national pathology archive 
(PALGA), in which all pathological reports from Dutch 
hospitals are collected. Trained registrars from the can-
cer registry collect characteristics of patients and 
tumours and details of primary treatment directly from 
the patients’ medical records. Vital status and date of 
death, if applicable, are verified by linkage to the 
municipal administration. Last date of linkage was 31 
December 2013. Follow-up was complete for all women, 
except those who emigrated out of the Netherlands 
before that time.
Patient involvement
Regular contact of SSiesling and MMAT-L with members 
and representatives of the breast cancer patients’ 
organisations the Netherlands Breast Cancer Associa-
tion (NBCA), Pink Ribbon, and A Sister’s Hope made the 
relevance of the outcome measures of this study clear 
for patients in making informed decisions about treat-
ment and screening. Patients were not further involved 
in the design of the study. Patients will be informed of 
the results of this study through the websites of the 
NBCA, Netherlands Cancer Registry, and Dutch Cancer 
Society and information evenings of Pink Ribbon and a 
Sister’s Hope.
Procedures
We subdivided patients into two time cohorts—1999-2005 
and 2006-12—on the basis of their breast cancer diagno-
sis. We chose these cohorts because from 2005 onwards 
chemotherapy schemes used were changed, trastu-
zumab was implemented,17  and Dutch guidelines were 
more liberal on who should receive adjuvant treat-
ment.18 We did analyses of the 1999-2005 cohort to con-
firm long term effects of traditional prognostic factors 
on survival in earlier times in our Dutch popula-
tion-wide cohort.
The following data were registered: date and age at 
breast cancer diagnosis, tumour characteristics, local 
and systemic therapy, vital status, second primary 
breast cancer, date of follow-up, and date of death. 
Local recurrence and occurrence of distant metastases 
were not registered by the cancer registry. Second pri-
mary breast cancer was defined as contralateral ductal 
carcinoma in situ or invasive epithelial breast cancer.20 
For local breast therapy, we used the most extensive 
surgery performed within one year of diagnosis. Data 
on whether patients had axillary lymph node dissection 
was registered all years, but data on sentinel lymph 
node biopsy procedure was registered only from 2011. 
Staging of primary tumours was based on the American 
Joint Committee on Cancer pathological cancer staging 
classification, seventh edition.21  If pathological tumour 
size was missing, we used clinical stage based on imag-
ing studies and clinical examination. Tumour stage was 
defined according to the greatest dimension of the larg-
est tumour size (Tis=ductal carcinoma in situ, T1a=≤0.5 
cm (including micro-invasion), T1b=>0.5 cm and ≤1 cm, 
T1c=>1 cm and ≤2 cm, T2=>2 cm and ≤5 cm, T3=>5 cm, 
T4=any size with direct extension to chest wall and/or 
skin). Lymph node status was described according to 
the number of regional lymph nodes with pathologi-
cally proven metastasis. Determination of lymph node 
positivity included results of sentinel lymph node 
biopsy. Lymph nodes with only isolated tumour cells 
were defined lymph node negative (N0=no pathologi-
cally proven positive lymph nodes, N1=1-3 positive, 
N2=4-9 positive, N3= ≥10 positive). Grading of tumours 
was based on the modified Bloom and Richardson grad-
ing system.22 Patients were considered oestrogen posi-
tive and progesterone positive in case of more than 10% 
nuclear staining. Hormone receptor status was regis-
tered from 2005 and onward, and HER2 status was reg-
istered in the Netherlands Cancer Registry from 2006 
onward.
statistical analysis
We used Pearson’s χ2 tests to calculate differences in 
stage distributions, lymph node status, and tumour 
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characteristics between the two time cohorts. We 
assessed differences in age distribution at breast cancer 
diagnosis as a continuous variable with the Mann-Whit-
ney U test and also assessed them with a χ2 test after 
categorical subdivision.
We defined overall survival as time from diagnosis of 
breast cancer to death from any cause.23  We defined rel-
ative survival as the relative excess risk of death or the 
observed survival of our study population divided by 
the expected survival of the corresponding general pop-
ulation by sex, age, and year of diagnosis.24 We calcu-
lated relative survival by using the Ederer II method. We 
used Dutch national life tables from the Central Bureau 
of Statistics (CBS) to estimate expected survival in the 
general population. We estimated relative five year sur-
vival rates and plotted relative survival curves stratified 
for tumour stage and nodal stage. Women were cen-
sored at date of last follow-up. As the follow-up of 
women in the two time cohorts differed considerably, 
all analyses were stratified for time period of breast can-
cer detection.
We developed Cox univariable and multivariable 
proportional hazard models for overall mortality for 
invasive breast cancers to estimate hazard ratios with 
95% confidence intervals. We used Cox regression uni-
variable and multivariable analyses only for invasive 
breast cancers, because hormone receptor and HER2 
status are not routinely determined for ductal carci-
noma in situ tumours in the Netherlands and including 
them in analyses would make inclusion of these factors 
into multivariable analyses impossible. To compare 
differences in hazard rates between the two time 
cohorts, we did additional analyses and limited maxi-
mum follow-up time for both cohorts to five years. We 
did not include hormone receptor and HER2 status, as 
these were unavailable in the oldest cohort; to compare 
hazard rates between the two time cohorts, we built a 
similar model but ductal carcinoma in situ was 
included. In multivariable analyses, we included all 
relevant clinicopathological variables and variables 
with a P value below 0.05 in univariable analyses. We 
found the assumption of proportional hazards to be 
valid by graphically plotting the log-log survival 
curves. We considered a two sided P value of 0.05 or 
less to be statistically significant. We analysed missing 
values as a separate unknown group within the same 
variable. We present hazard ratios with corresponding 
95% confidence intervals and used the rule of four to 
ensure that the rounding error was less than 1.3% for 
all ratios.25 We used SPSS Statistics for Windows (ver-
sion 20.0) for statistical analyses and SAS (version 9.4) 
for relative survival.
Results
Characteristics of patients and tumours
In the Netherlands, 173 797 female patients were diag-
nosed as having primary breast cancer with known 
tumour stage between 1999 and 2012: 80 228 (46%) from 
1999 to 2005 and 93 569 (54%) from 2006 to 2012. 
Tumour size was defined clinically, instead of patholog-
ically, for 11 929 (6.9%). Median age at diagnosis was 
59.3 years for the cohort of 1999-2005 and 60.0 years for 
the 2006-12 cohort; continuous age distribution was 
comparable (P=0.169). However, when we categorised 
age at breast cancer diagnosis (supplementary figure), 
we found a significant difference between the distribu-
tion in age categories of 1999-2005 and 2006-12 
(P<0.001). Compared with 1999-2005, tumours diag-
nosed in 2006-12 were smaller (≤T1 65% (60 570/93 569) 
versus 60% (48 031/80 228); P<0.001) and were more 
often lymph node negative (N0 68% (63 544/93 569) ver-
sus 65% (52 238/80 228); P<0.001) and low grade (inva-
sive cancers grade 1 21% (17 334/93 569) versus 16% 
(11 939/80 228); P<0.001). Patients recently diagnosed 
as having breast cancer more often had breast conserv-
ing therapy (54% (50 313/93 569) versus 48% 
(38 638/80 228); P<0.001), whereas axillary node dissec-
tion was performed less often (P<0.001). Uptake of 
radiotherapy and systemic therapy was increased 
(P<0.001): hormonal therapy by 10%, chemotherapy by 
7%, targeted therapy (mainly trastuzumab) by 7%, and 
the combination by 7%. Hormone receptor status was 
available for invasive breast cancers in the most recent 
cohort of 2006-12 only. Oestrogen receptor was negative 
in 13 876 (17%), positive in 67 993 (82%), and unknown 
in 1352 (2%) of 83 221 invasive breast cancers diagnosed 
in 2006-12. Progesterone was negative in 26 268 (32%), 
positive in 53 557 (64%), and unknown in 3396 (4%). 
HER2 status was negative in 67 418 (81%), positive in 
10 899 (13%), and unknown in 4904 (6%). Table 1 shows 
further results.
relative and overall survival
Median follow-up was 9.8 (range 0-15) years for the 
first cohort (1999-2005) and 3.9 (0-8) years for the sec-
ond cohort (2006-12). During follow-up, 27 924 events 
occurred in the first cohort and 11 177 in the second 
cohort. We plotted relative survival curves for both 
tumour stage (fig 1 ) and nodal stage (fig 2 ). Compared 
with 1999-2005, five year relative survival rates and 
overall survival rates were higher for the 2006-12 
cohort for all tumour and nodal stages (table 2). Rela-
tive survival of ductal carcinoma in situ was 100% 
after 15 years for the 1999-2005 cohort and 101% after 8 
years for the 2006-12 cohort. Relative survival 
decreased with increasing tumour and nodal stages, 
except for T1b versus T1a (1999-2005 100% v 99%; 
2006-12 101% v 100%). Relative survival in the 1999-
2005 cohort did not decrease after nine years for all 
tumour sizes T1c or smaller and after 13 years for 
tumours T2 or larger. In the 2006-12 cohort, no 
decrease in relative survival was seen in tumour sizes 
T2 or smaller after six years and for tumour sizes larger 
than T2 after seven years.
Prognostic factors: cohort 1999-2005
We did Cox regression univariable and multivariable 
analyses only for invasive breast cancers. Patients with 
breast surgery classified as “other” were excluded from 
analyses, owing to the small numbers (n=93 in all 
patients with invasive breast cancer in both time 
cohorts) and heterogeneity of this group. Of 73 245 
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patients diagnosed as having invasive breast cancer 
between 1999 and 2005, 26 717 (37%) died during fol-
low-up. With univariable and multivariable Cox 
 regression analyses, we assessed influence on overall 
mortality of age, second primary breast cancer, tumour 
and nodal stage, grade, morphology, breast surgery, 
axillary lymph node dissection, chemotherapy, hor-
monal therapy, targeted therapy, and radiotherapy. Cox 
regression univariable and multivariable analyses 
showed that after correction for the above factors, 
higher tumour stage and lymph node positivity 
increased overall mortality (table 3).
Prognostic factors: cohort 2006-12
In the 2006-12 cohort, 10 778 (13%) of 83 191 patients 
with invasive breast cancer died during follow-up. In 
Cox regression univariable analyses, all clinicopatho-
logical variables were significantly associated with 
overall mortality (table 4). In multivariable analysis, 
we adjusted for age, tumour and nodal stage, grade, 
morphology, hormone receptor and HER2 status, 
breast surgery, axillary lymph node dissection, che-
motherapy, hormonal therapy, targeted therapy, 
radiotherapy, and second primary breast cancer. 
Tumour stage and nodal stage were both significantly 
table 1 | Patient and tumour characteristics and treatment by time period in patients with breast cancer in netherlands Cancer registry, 1999-2012. 
values are numbers (percentages) unless stated otherwise
Characteristic/treatment 1999-2005 (n=80 228) 2006-12 (n=93 569) total (n=173 797) P value*
Median (range) age at diagnosis, years 59.3 (17.1-100.4) 60.0 (18.9-103.1) 59.7 (17.1-103.1) 0.169
Second primary breast cancer 5539 (7) 3733 (4) 9272 (5) <0.001
Pathological tumour category†:
 Ductal carcinoma in situ 6920 (9) 10 348 (11) 17 268 (10)
<0.001
 T1a 2398 (3) 3846 (4) 6244 (4)
 T1b 9599 (12) 12 213 (13) 21 812 (13)
 T1c 29 114 (36) 34 163 (37) 63 277 (36)
 T2 26 624 (33) 27 946 (30) 54 570 (31)
 T3 2711 (3) 3213 (3) 5924 (3)
 T4 2862 (4) 1840 (2) 4702 (3)
Pathological node category:
 N0 52 238 (65) 63 544 (68) 115 782 (67)
<0.001
 N1 19 012 (24) 21 901 (23) 40 913 (24)
 N2 5985 (8) 5400 (6) 11 385 (7)
 N3 2993 (4) 2724 (3) 5717 (3)
B&R grade, DCIS only:
 Grade 1 986 (14) 1667 (16) 2653 (15)
<0.001
 Grade 2 1798 (26) 3162 (31) 4960 (29)
 Grade 3 (including anaplastic) 2863 (41) 4842 (47) 7705 (45)
 Unknown 1273 (18) 677 (7) 1950 (11)
B&R grade, invasive cancers only:
 Grade 1 11 939 (16) 17 334 (21) 29 273 (19)
<0.001
 Grade 2 26 923 (37) 32 672 (39) 59 595 (38)
 Grade 3 (including anaplastic) 21 119 (29) 22 269 (27) 43 388 (28)
 Unknown 13 327 (18) 10 946 (13) 24 273 (16)
Morphology, invasive cancers only:
 Ductal carcinoma or ductal mixed type 56 144 (77) 66 124 (80) 122 268 (78)
<0.001 Lobular carcinoma 8133 (11) 9133 (11) 17 003 (11)
 Other 9031 (12) 7964 (10) 17 266 (11)
Breast surgery:
 No surgery 3319 (4) 4877 (5) 8196 (5)
<0.001
 Breast conserving therapy 38 638 (48) 50 313 (54) 88 951 (51)
 Mastectomy 38 040 (47) 38 307 (41) 76 347 (44)
 Other 231 (0) 72 (0) 303 (0)
Axillary lymph node dissection 45 438 (57) 31 021 (33) 76 459 (44) <0.001
Systemic therapy‡ 42 185 (53) 56 402 (60) 98 587 (57) <0.001
Chemotherapy 24 029 (30) 34 819 (37) 58 848 (34) <0.001
Hormonal therapy 31 320 (39) 45 357 (49) 76 677 (44) <0.001
Targeted therapy 725 (1) 7411 (8) 8136 (5) <0.001
Radiotherapy 46 925 (59) 59 100 (63) 106 025 (61) <0.001
All percentages were calculated vertically. Total of percentages may not equal 100% owing to rounding. Missing values were analysed as separate unknown group within same variable.
B&R=Bloom and Richardson; DCIS=ductal carcinoma in situ; N0=no pathologically assessed regional lymph nodes with metastasis/isolated tumour cells; N1=metastasis in 1-3 regional lymph 
nodes; N2=metastasis in 4-9 ipsilateral regional lymph nodes; N3=metastasis in ≥10 regional lymph nodes; T1a=≤0.5 cm (including micro-invasion); T1b=>0.5 cm and ≤1 cm; T1c=>1 cm and ≤2 
cm; T2=>2 cm and ≤5 cm; T3=>5 cm; T4=any size with direct extension to chest wall and/or skin.
*Two sided P value for difference between two time cohorts; differences in age distribution at diagnosis were calculated from Mann-Whitney U test; all other differences were obtained from χ2 test.
†Difference in tumour stage distribution between two time cohorts excluding DICS was also P<0.001.
‡Includes chemotherapy, hormonal therapy, and all targeted therapy (mainly trastuzumab).
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associated with overall mortality, although tumour 
size had a significant influence only when larger than 
1 cm (T1b v T1a: hazard ratio 1.04, 95% confidence 
interval 0.88 to 1.22; P=0.677). Positive hormone recep-
tors lowered the hazard rate of death by 20-30% 
(P<0.001), in contrast to positive HER2 status which 
lost significance in multivariable analyses (hazard 
ratio 1.00, 0.93 to 1.08; P=0.933). Axillary lymph node 
dissection increased the hazard rate (hazard ratio 1.29, 
1.21 to 1.38; P<0.001), and breast conserving therapy 
decreased it (0.87, 0.81 to 0.93; P<0.001). Treatment 
with chemotherapy, hormonal therapy, targeted ther-
apy, and radiotherapy all led to lower hazard rates 
(P<0.001). Contrary to univariable analysis, second 
primary breast cancer had no effect on overall mortal-
ity in multivariable analysis (hazard ratio 1.01, 0.93 to 
1.11; P=0.762).
Prognostic factors: comparison between 1999-2005 
and 2006-12 cohorts
To compare the hazard rates of the two time cohorts, we 
also did multivariable Cox regression analyses restrict-
ing follow-up time to a maximum of five years (supple-
mentary table). Hazard rates for overall mortality were 
lower for all tumour stages and lymph node stages in 
2006-12 compared with 1999-2005. Hazard rates for duc-
tal carcinoma in situ were significantly lower than the 
reference category T1a in both time cohorts.
discussion
In this Dutch population-wide prospective cohort 
study, we estimated the influence of well established 
prognostic factors in 173 797 female patients with 
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 primary breast cancer in two time cohorts: 1999-2005 
and 2006-12. Notably, we observed a 17% increase in 
diagnosis of breast cancer between the two time peri-
ods. Part of this might be explained by the ageing 
society, as increasing age is a major risk factor for 
breast cancer. Between 1999-2005 and 2006-12, the 
Dutch female population grew by approximately 2.7% 
but the female population aged 60-69 years grew by 
approximately 23%.26 Median age at diagnosis of 
breast cancer was around 59 years, with a peak 
around the menopause (age cohort 50-59 years). 
Tumours diagnosed in the most recent cohort were 
smaller, more often lymph node negative, and more 
often low grade than tumours from the first time 
period. Five year relative survival rates improved in 
the recent cohort in all tumour stages, to 100% in all 
tumours 1 cm or smaller and to 98% for tumours 
between 1 cm and 2 cm, and improved increasingly 
with larger tumour size. Relative survival increased 
especially in women aged over 75 years.
In univariable and multivariable analyses, both 
tumour stage and lymph node status had a significant 
influence on overall survival in both cohorts (P<0.001). 
The importance of early detection is dual—with 
increasing tumour size, lymph node positivity also 
increases.27 We determined the influence of stage cor-
rected for both tumour biology and treatment. We 
found no difference in hazard rate for breast cancers 
sized 1 cm or smaller, neither with long term follow-up 
nor in recent times (2006-12 T1b v T1a, P=0.677). When 
node negative, these patients do not regularly get 
adjuvant therapy in the Netherlands even when oes-
trogen receptor negative. With 100% five year relative 
survival rates, simplifying the next edition of the 
pathological tumour classification by combining T1a 
and T1b into one extremely favourable category seems 
justified.
Patients with breast cancer diagnosed between 2006 
and 2012 had breast conserving therapy more often and 
axillary lymph node dissection less often (P<0.001), 
owing to the increasing use of sentinel lymph node 
biopsies over the years.14  Although tumour stage was 
more favourable in patients in the 2006-12 cohort, 
uptake of all forms of (neo-)adjuvant systemic therapy 
was increased (P<0.001), mainly due to the extended 
indication in Dutch guidelines from 2005 onward,18 as 
well as possibly to down staging of tumours treated 
with neo-adjuvant therapy.
Surgery is of prime importance for survival, and 
breast conserving therapy conferred a favourable sur-
vival compared with mastectomy despite correction 
for stage, age, and adjuvant therapies (hazard ratio 
0.87, 0.81 to 0.93; P<0.001). In the 2006-12 cohort, axil-
lary lymph node dissection, advised only for patients 
with positive lymph nodes confirmed by sentinel node 
table 2 | estimated five year overall survival and relative survival rates according to 
tumour stage, nodal stage, and age at breast cancer diagnosis category by time period 
in patients with breast cancer in netherlands Cancer registry, 1999-2012
Characteristic
Overall survival* (%) relative survival† (%)
1999-2005 2006-12 1999-2005 2006-12
All patients 83 88 91 96
Tumour stage:
 DCIS 94 96 100 101
 T1a 93 95 99 100
 T1b 93 95 100 101
 T1c 88 91 96 98
 T2 76 82 86 92
 T3 63 73 70 81
 T4 44 45 57 59
Nodal stage :
 N0 85 90 95 98
 N1 84 88 91 95
 N2 71 81 77 86
 N3 55 66 59 71
Age at breast cancer diagnosis:
 <50 years 89 94 90 95
 50-75 years 88 93 94 97
 >75 years 51 56 83 91
DCIS=ductal carcinoma in situ.
*Time from breast cancer diagnosis to death from any cause.
†Observed survival divided by expected survival of corresponding general population, matched by sex, age, and 
year of diagnosis; calculated using Ederer II method. Women were censored at date of last follow-up.
table 3 | Cox univariable and multivariable analyses of clinicopathological variables for overall mortality in patients with 
invasive breast cancer in netherlands Cancer registry, 1999-2005
Clinicopathological variables
univariable analyses Multivariable analyses*
Hazard ratio (95% Ci) P value no Hazard ratio (95% Ci) P value
Pathological tumour category:
 T1a Reference 2393 Reference
 T1b 1.07 (0.97 to 1.18) 0.195 9589 1.09 (0.99 to 1.20) 0.098
 T1c 1.50 (1.37 to 1.64) <0.001 29 100 1.40 (1.27 to 1.53) <0.001
 T2 2.74 (2.50 to 3.00) <0.001 26 597 1.91 (1.74 to 2.10) <0.001
 T3 4.2 (3.76 to 4.6) <0.001 2710 2.60 (2.34 to 2.89) <0.001
 T4 7.6 (6.9 to 8.4) <0.001 2856 2.77 (2.50 to 3.07) <0.001
Pathological node category:
 N0 Reference 45 280 Reference
 N1 1.04 (1.01 to 1.07) 0.018 18 993 1.35 (1.30 to 1.39) <0.001
 N2 1.78 (1.72 to 1.85) <0.001 5981 2.19 (2.08 to 2.30) <0.001
 N3 3.02 (2.89 to 3.17) <0.001 2991 3.48 (3.28 to 3.69) <0.001
*Corrected for age, tumour grade and morphology, breast surgery, axillary lymph node dissection, chemotherapy, hormonal therapy, targeted therapy, 
radiotherapy, and second primary breast cancer.
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table 4 | Cox univariable and multivariable analyses of clinicopathological variables for overall mortality in patients with invasive breast cancer in 
netherlands Cancer registry, 2006-12
Clinicopathological variables
univariable analyses Multivariable analyses*
Hazard ratio (95% Ci) P value no Hazard ratio (95% Ci) P value
Age at diagnosis in years 1.07 (1.07 to 1.07) <0.001 83 191 1.04 (1.04 to 1.05) <0.001
Pathological tumour category:
 T1a Reference 3840 Reference
 T1b 0.93 (0.79 to 1.09) 0.339 12 207 1.04 (0.88 to 1.22) 0.677
 T1c 1.61 (1.39 to 1.85) <0.001 34 156 1.54 (1.33 to 1.78) <0.001
 T2 3.53 (3.07 to 4.1) <0.001 27 937 2.17 (1.87 to 2.52) <0.001
 T3 5.6 (4.8 to 6.6) <0.001 3212 2.78 (2.36 to 3.27) <0.001
 T4 14.6 (12.6 to 17.1) <0.001 1839 3.32 (2.83 to 3.90) <0.001
Pathological node category:
 N0 Reference 53 223 Reference
 N1 1.01 (0.96 to 1.06) 0.734 21 851 1.25 (1.17 to 1.32) <0.001
 N2 1.66 (1.56 to 1.78) <0.001 5396 2.36 (2.16 to 2.58) <0.001
 N3 3.19 (2.97 to 3.41) <0.001 2721 4.0 (3.66 to 4.4) <0.001
Bloom and Richardson grade:
 Grade 1 Reference 17 327 Reference
 Grade 2 1.42 (1.33 to 1.53) <0.001 32 662 1.18 (1.10 to 1.27) <0.001
 Grade 3 (including anaplastic) 2.49 (2.33 to 2.67) <0.001 22 263 1.69 (1.56 to 1.82) <0.001
 Unknown 6.2 (5.8 to 6.6) <0.001 10 939 1.68 (1.54 to 1.83) <0.001
Morphology:
 Ductal carcinoma or ductal mixed Reference 66 104 Reference
 Lobular carcinoma 1.20 (1.13 to 1.27) <0.001 9127 0.91 (0.86 to 0.97) 0.003
 Other 1.64 (1.55 to 1.73) <0.001 7960 0.94 (0.89 to 1.00) 0.040
Oestrogen receptor status:
 Negative Reference 13 873 Reference
 Positive 0.55 (0.53 to 0.58) <0.001 67 967 0.71 (0.66 to 0.77) <0.001
 Unknown 1.21 (1.08 to 1.37) 0.001 1351 1.00 (0.85 to 1.18) 0.972
Progesterone receptor status:
 Negative Reference 26 261 Reference
 Positive 0.58 (0.56 to 0.60) <0.001 53 535 0.81 (0.77 to 0.85) <0.001
 Unknown 0.93 (0.85 to 1.01) 0.069 3395 0.81 (0.72 to 0.90) <0.001
HER2 status:
 Negative Reference 67 393 Reference
 Positive 1.06 (1.00 to 1.12) 0.047 10 897 1.00 (0.93 to 1.08) 0.933
 Unknown/inconclusive 2.88 (2.73 to 3.04) <0.001 4901 0.94 (0.88 to 1.00) 0.045
Breast surgery:
 Mastectomy Reference 34 421 Reference
 Breast conserving therapy 0.389 (0.372 to 0.41) <0.001 44 117 0.87 (0.81 to 0.93) <0.001
 No surgery 7.6 (7.2 to 7.9) <0.001 4653 4.1 (3.78 to 4.5) <0.001
Axillary lymph node dissection:
 No Reference 52 353 Reference
 Yes 1.18 (1.14 to 1.23) <0.001 30 838 1.29 (1.21 to 1.38) <0.001
Chemotherapy:
 No Reference 48 417 Reference
 Yes 0.52 (0.50 to 0.54) <0.001 34 774 0.86 (0.80 to 0.92) <0.001
Hormonal therapy:
 No Reference 37 931 Reference
 Yes 1.21 (1.17 to 1.26) <0.001 45 260 0.64 (0.61 to 0.68) <0.001
Targeted therapy:
 No Reference 75 797 Reference
 Yes 0.55 (0.51 to 0.60) <0.001 7394 0.58 (0.52 to 0.65) <0.001
Radiotherapy:
 No Reference 29 569 Reference
 Yes 0.353 (0.340 to 0.367) <0.001 53 622 0.69 (0.64 to 0.73) <0.001
Second primary breast cancer:
 No Reference 79 889 Reference
 Yes 1.12 (1.03 to 1.23) 0.010 3302 1.01 (0.93 to 1.11) 0.762
*Adjusted for age, tumour and nodal stage, grade, morphology, hormone receptor and HER2 status, breast surgery, axillary lymph node dissection, chemotherapy, hormonal therapy, targeted 
therapy, radiotherapy, and second primary breast cancer.
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biopsy or cytology, decreased overall survival in mul-
tivariable analysis (hazard ratio 1.29, 1.21 to 1.38; 
P<0.001).
In multivariable analyses, chemotherapy decreased 
the hazard of death by approximately 14% in the 2006-
12 cohort. HER2 status was known for the 2006-12 
cohort, but after adjustment for targeted therapies such 
as trastuzumab, HER2 positive status was no longer sig-
nificantly associated with overall survival. Apparently, 
trastuzumab is so effective that, with its current use in 
tumours larger than 1 cm, the effect of HER2 positivity 
on survival becomes negligible. The group with 
unknown HER2 status contained a large number of 
patients with inconclusive HER2 status, who might well 
be HER2 positive but who did not all receive targeted 
therapy. This group had significantly higher hazard 
rates, which endorses the necessity of targeted therapy 
in HER2 positive patients.
Comparison with other studies
Owing to the relatively favourable survival rates of 
patients with breast cancer, long follow-up and large 
groups of patients are needed to provide sufficient 
power to detect differences in overall survival. A recent 
Lancet publication with global data showed age stan-
dardised net survival with breast cancer of 80% or more 
in 34 countries and an increase worldwide but had no 
data on factors influencing it.1  Our more recent results 
from 2006-12 even indicated a five year relative survival 
rate of 96%. Another recent study compared breast can-
cer recurrence and outcome patterns in 3589 patients 
treated from 1986 to 1992 matched one to one with 
patients from 2004-08.3  The authors describe a lower 
hazard rate of breast cancer relapse and a lower hazard 
rate of death in the later time period, but similar out-
come patterns by oestrogen receptor and HER2 receptor 
status. Their study was not designed to identify current 
prognostic factors. This study is difficult to compare 
with ours, as it differs with respect to the timeframes 
chosen for the cohorts, the matched design, and the 
much lower number of patients. Another study by Duffy 
et al also shows considerably better survival of node 
negative versus node positive breast cancers in 9040 
patients with breast cancer from 1998 to 2003 in the east 
of England.28
strengths and limitations of study
The nationwide registration in the Netherlands of 
breast cancer incidence, pathology, and treatment data 
by the Netherlands Cancer Registry, combined with 
linkage to the municipal administration for vital status 
verification, provides unique and reliable population 
based data. However, our study has some limitations. 
Owing to the nature of our research question, a large 
difference in follow-up existed between the two 
cohorts. In the supplementary table, follow-up for both 
cohorts was restricted to five years maximum to make 
comparison possible. However, changes in long term 
survival between the two cohorts might not be fully 
picked up at this time, because of the shorter follow-up 
time of the most recent cohort. Comparing 10 year and 
15 year survival analyses of both time cohorts in the 
future will be informative. Furthermore, between 1999 
and 2005, it was not standard of care in the Nether-
lands to evaluate hormone and HER2 status, making 
adjustment for these factors in our oldest cohort 
impossible. As our main interest was to identify and 
quantify the effect of traditional prognostic factors in 
the current era, we solved these limitations partly by 
analysing the two time cohorts separately. The 1999-
2005 cohort gives insights on the effect on long term 
survival. Finally, although we have extensive clinico-
pathological data, no data were available on patients’ 
comorbidity, which probably influences both primary 
outcome (survival) and type of treatment, and some 
influence on tumour stage and lymph node stage at 
detection cannot be excluded.
Conclusion and policy implications
In conclusion, our population-wide study in 173 797 
female patients is the first to use such recent data to 
assess the effect of traditional prognostic factors such 
as tumour size and nodal status on survival. Our results 
can aid both policy makers on national programmes 
and physicians in clinical decision making, as well as 
informing patients about the effect of stage and treat-
ment choices on their prognosis. Furthermore, our data 
are of special importance for research trials that often 
use prognosis per tumour stage as primary outcomes. 
Tumour size and nodal status still had a significant and 
major influence independent of tumour biology in the 
current era of more conservative surgery and the new, 
more effective, and widely applied systemic (neo-)
adjuvant therapies. Our results emphasise the impor-
tance of tumour stage at diagnosis of breast cancer, as 
it still greatly affects overall survival.
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